MERCK & CO. INC. (MRK) Stock News
NYSE:MRK - New York Stock Exchange, Inc. - US58933Y1055 - Common Stock - Currency: USD
MRK Latest News, Press Relases and Analysis
MERCK & CO. INC. (NYSE:MRK) – A Strong Dividend Stock with Solid Fundamentals
MERCK & CO. (NYSE:MRK) offers a strong 4% dividend yield, consistent growth, and solid profitability, making it a top pick for income investors. The stock is also attractively valued.
Explore the top gainers and losers within the S&P500 index in today's session.
Let's delve into the developments on the US markets in the middle of the day on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.
FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health
Verona Pharma (VRNA) Skyrockets 20.6% on $10-Billion Merger Deal with Merck
Verona Pharma plc (NASDAQ:VRNA) is one of the 10 Stocks Going Wild. Verona Pharma surged by 20.62 percent on Wednesday to end at $104.77 per share following news that it was being acquired by US-based pharmaceutical company Merck for $10 billion. In a statement, Merck said that it entered into a definitive agreement with Verona Pharma […]
Mentions: VRNA
Stock market today: Dow, S&P 500, Nasdaq jump as Nvidia's surge to milestone boosts tech
President Trump has ratcheted up trade tensions with US trade partners.
Top Stock Movers Now: Nvidia, AES, WPP, and More
Continuing questions about the impact of Trump administration tariffs caused U.S. equities to be higher but little changed at midday.
Mentions: NVDA
Stock market today: Dow, S&P 500, Nasdaq edge higher as Nvidia's market cap hits $4T, Trump unveils more tariff letters
President Trump has ratcheted up trade tensions with US trade partners.
What You Need To Know Ahead of Merck's Earnings Release
Merck is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings dip.
Mentions: NVDA
Verona Pharma Stock Soars to All-Time High as Merck Buys Firm for $10B
Merck is paying about $10 billion for Verona Pharma, expanding its respiratory disease drug portfolio.
UBS Affirms Merck & Co’s (MRK) ‘Buy’ Rating on HPV Vaccine Prospects
Merck & Co., Inc. (NYSE:MRK) is one of the 10 best defensive stocks to buy in a volatile market. On July 2, UBS reiterated a ‘Buy’ rating on the stock and a $105 price target. According to analyst Trung Huynh, the company’s human papillomavirus (HPV) vaccine, Gardasil, is a key driver of growth. Huynh insists […]
Merck Plots $10 Billion Takeover Of COPD Drugmaker Verona Pharma
The takeover target just launched its first drug last summer. Shares have mostly trended higher since.
Mentions: VRNA
Merck Strikes $10 Billion Deal to Buy Verona Pharma
Merck (MRK) on Wednesday agreed to acquire UK-based biopharmaceutical company Verona Pharma (VRNA) i
Merck Agrees to Buy Verona Pharma for About $10 Billion
Merck & Co. agreed to buy UK biotech Verona Pharma Plc for about $10 billion to offset the looming loss of patent protection on its top-selling cancer drug.
Merck Nears $10 Billion Deal for Drugmaker Verona, FT Reports
Merck & Co. is closing in on an approximately $10 billion deal to acquire respiratory drugmaker Verona Pharma, the Financial Times reported.
Exelixis Surges 35.2% in Three Months: Buy or Sell the Stock?
EXEL surges 35.2% in three months as strong Cabometyx sales and zanzalintinib trial success fuel investor optimism.
SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca
Summit Therapeutics jumps 9% as AZN eyes a potential $15 billion licensing deal for its cancer drug, ivonescimab.
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Merck & Co (MRK) Announces the Approval of ENFLONSIA
Merck & Co., Inc. (NYSE:MRK) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 26, Merck & Co., Inc. (NYSE:MRK) announced that the Advisory Committee on Immunization Practices has approved ENFLONSIA for preventing respiratory syncytial virus in infants younger than 8 months. The recommendation is provisional and is pending the […]
Mentions: SNY
Uncover the latest developments among S&P500 stocks in today's session.
Get insights into the S&P500 index performance on Thursday. Explore the top gainers and losers within the S&P500 index in today's session.
What's going on in today's session: S&P500 gap up and gap down stocks
Thursday's session is showcasing interesting market movements in the S&P500 index, with notable gap up and gap down stocks. Stay updated with the gapping S&P500 stocks in today's session.
MERCK & CO. INC. (NYSE:MRK) – A Strong Value Candidate in Healthcare
MERCK & CO. (NYSE:MRK) is an undervalued pharmaceutical stock with strong profitability, a healthy balance sheet, and a reliable dividend, making it a candidate for value investors.